New clinical opportunities for mineralocorticoid receptor antagonists: focus on antifibrotic effects

Abstract

Mineralocorticoid receptor antagonists have been successfully used for many years to treat patients with primary hyperaldosteronism, refractory arterial hypertension and chronic heart failure. The increased interest in this drug in recent years is due to new information about its antifibrotic and antiproliferative effects, both cardiac and extracardiac. The article also discusses the possibility of using spironolactone in patients with the new coronavirus infection SARS-CoV-2 (COVID-19).

Keywords

• aldosterone antagonists
• spironolactonum
• antifibrotic effect
• chronic heart failure
• arterial hypertension
• covid-19